| 000 | 01869 a2200553 4500 | ||
|---|---|---|---|
| 005 | 20250515154227.0 | ||
| 264 | 0 | _c20090707 | |
| 008 | 200907s 0 0 eng d | ||
| 022 | _a0269-2813 | ||
| 024 | 7 |
_a10.1111/j.1365-2036.2008.03779.x _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aScherzer, T M | |
| 245 | 0 | 0 |
_aEfficacy and safety of antiviral therapy in patients with Crohn's disease and chronic hepatitis C. _h[electronic resource] |
| 260 |
_bAlimentary pharmacology & therapeutics _cSep 2008 |
||
| 300 |
_a742-8 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAntiviral Agents _xtherapeutic use |
| 650 | 0 | 4 | _aComorbidity |
| 650 | 0 | 4 |
_aCrohn Disease _xdrug therapy |
| 650 | 0 | 4 | _aDrug Therapy, Combination |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aHepacivirus _xisolation & purification |
| 650 | 0 | 4 |
_aHepatitis C, Chronic _xdrug therapy |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunocompromised Host _ximmunology |
| 650 | 0 | 4 |
_aImmunosuppressive Agents _xtherapeutic use |
| 650 | 0 | 4 | _aInterferon alpha-2 |
| 650 | 0 | 4 |
_aInterferon-alpha _xtherapeutic use |
| 650 | 0 | 4 | _aLeukocyte Count |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aPolyethylene Glycols _xtherapeutic use |
| 650 | 0 | 4 | _aPolymerase Chain Reaction |
| 650 | 0 | 4 |
_aRNA, Viral _xblood |
| 650 | 0 | 4 | _aRecombinant Proteins |
| 650 | 0 | 4 | _aRetrospective Studies |
| 650 | 0 | 4 |
_aRibavirin _xtherapeutic use |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aStaufer, K | |
| 700 | 1 | _aNovacek, G | |
| 700 | 1 | _aSteindl-Munda, P | |
| 700 | 1 | _aSchumacher, S | |
| 700 | 1 | _aHofer, H | |
| 700 | 1 | _aFerenci, P | |
| 700 | 1 | _aVogelsang, H | |
| 773 | 0 |
_tAlimentary pharmacology & therapeutics _gvol. 28 _gno. 6 _gp. 742-8 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/j.1365-2036.2008.03779.x _zAvailable from publisher's website |
| 999 |
_c18593479 _d18593479 |
||